NSW Health Continues to Use Machine Known to Produce Inaccurate Results to Test Child Blood Lead Levels

Why It Matters

Inaccurate lead testing jeopardizes early intervention for vulnerable children, undermining public‑health goals and eroding community trust in health authorities.

Key Takeaways

• LeadCare II yields +/-6 µg/dL error margin.
• TGA removed device from ARTG in 2020.
• NSW Health relies on point‑of‑care for rapid screening.
• Families report inadequate follow‑up after elevated lead results.
• Broken Hill children still face environmental lead exposure.

Pulse Analysis

Broken Hill’s legacy of mining has left a persistent environmental lead threat, making accurate blood‑lead testing a cornerstone of child health protection. Even low concentrations, such as 3.5 µg/dL, are linked to cognitive and behavioural deficits, prompting Australian guidelines to trigger investigations at five micrograms per deciliter. When screening tools provide unreliable data, clinicians may miss early signs, delaying interventions that could prevent lifelong impairments.

The LeadCare II system, once widely deployed for its finger‑prick convenience, was withdrawn from the Australian Register of Therapeutic Goods in 2020 after the Therapeutic Goods Administration identified a +/- 6 µg/dL error range. NSW Health, however, secured a special arrangement allowing continued use in the Far West Local Health District, citing the need for rapid community‑wide screening. Critics argue this trade‑off sacrifices diagnostic accuracy for speed, especially when false negatives can leave children undiagnosed and families without needed support.

The controversy spotlights broader policy challenges: balancing immediate access to testing with the obligation to provide reliable results and comprehensive follow‑up. Health officials must accelerate the transition to laboratory‑based venous testing or adopt validated alternatives, while ensuring outreach programs address the socioeconomic barriers that limit uptake. Transparent communication and robust remediation funding will be essential to restore public confidence and safeguard the next generation from lead‑related harm.